Abstract
Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.
Original language | English (US) |
---|---|
Pages (from-to) | 2205-2214 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 12 |
Issue number | 19 |
DOIs | |
State | Published - Oct 2016 |
Externally published | Yes |
Keywords
- Albumin
- Albumin-corrected calcium
- Malignant melanoma
- Serum calcium
ASJC Scopus subject areas
- Oncology
- Cancer Research